Last edition
News about "TNBC"
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
TNBC | 26/06/2026 | By News Bureau | 179
Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC
Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.
TNBC | 13/02/2026 | By News Bureau | 199
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
TNBC | 04/02/2026 | By News Bureau | 179
Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer
Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.
TNBC | 08/01/2026 | By News Bureau | 298
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy